Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia

Reem Karmali*, Melissa L. Larson, Jamile M. Shammo, Sanjib Basu, Kent Christopherson, Jeffrey A. Borgia, Parameswaran Venugopal

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Our objective was to explore associations of circulating factors implicated in insulin-like growth factor-1 receptor (IGF-1R) signaling with clinical outcomes of patients with acute myeloid leukemia (AML). Pretreatment blood samples from patients with non-M3 AML (n = 30) were collected prospectively and levels of IGF binding proteins (IGFBPs) 1-7 and IGF-1 (free and total) were established at diagnosis and statistically evaluated. Baseline levels of IGFBP-1 and-6 below respective thresholds of 8.8 ng/mL and 237 ng/mL were associated (p = 0.0347 and 0.0099, respectively) with superior progression-free survival, whereas baseline levels of IGFBP-1,-2,-6 and-7 below the respective thresholds of 8.8, 28.8, 237 and 119 ng/mL were strongly associated (p = 0.0004, 0.0085, 0.0031, 2.46 × 10-7, respectively) with improved overall survival. These findings provide promising evidence that IGFBP signatures could be used as predictive tools in AML, with applications in remission surveillance and the development of IGFBP-directed biologic therapy.

Original languageEnglish (US)
Pages (from-to)3135-3142
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number11
DOIs
StatePublished - Nov 2 2015

Keywords

  • AML
  • IGF-1
  • IGFBPs
  • Luminex
  • clinical outcome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this